Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Better together
April 2020
SHARING OPTIONS:

SOUTH SAN FRANCISCO, Calif.—VistaGen Therapeutics shared positive preclinical data in February for AV-101, an oral NMDAR (N-methyl-D-aspartate receptor) antagonist prodrug, when administered in combination with probenecid. The data suggest that the combination leads to a substantially increased brain concentration of AV-101 and its active metabolite, 7-chlorokynurenic acid (7-Cl-KYNA)—a seven-fold and 35-fold increase, respectively. Abnormal NMDAR function is linked to several central nervous system diseases. Unlike other NMDAR antagonists, AV-101 is not an ion channel blocker and does not have the side effects associated with similar antagonists such as ketamine. AV-101 has received Fast Track designation from the FDA as a potential adjunctive treatment for major depressive disorder and as a non-opioid treatment for neuropathic pain.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.